FDA Awards Priority Review Voucher to Vertex Pharmaceuticals for Rare Pediatric Disease Product

Summary

The FDA has awarded a priority review voucher to Vertex Pharmaceuticals, Inc. for its rare pediatric disease product application, CASGEVY, which is manufactured by Vertex Pharmaceuticals, Inc. and is the first to meet the criteria for the voucher under the FD&C Act.